Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 209

recruiting
3 987
countries
28
conditions
2 109

10 381 trials match your criteria

Systemic lupus erythematosus

Recruiting

Study on the Safety and Effectiveness of CABA-201, Fludarabine Phosphate, and Cyclophosphamide in Patients with Active Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CABA-201

Adenocarcinoma of colon+1

Recruiting

Study on Atezolizumab with FOLFOX for Stage III Colon Cancer with Deficient DNA Mismatch Repair

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Uveal melanoma

Recruiting

Title: Comparing tebentafusp treatment versus observation in patients with high-risk eye melanoma (uveal melanoma) after initial treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tebentafusp

Ventricular extrasystoles

Recruiting

Study of drug combination therapy in asymptomatic patients with frequent premature ventricular contractions and normal heart function to prevent left ventricular dysfunction

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bisoprolol Fumarate

Non-small cell lung cancer+1

Recruiting

Study of Durvalumab, Tremelimumab, Chemotherapy, and Radiotherapy for Patients with Newly Diagnosed Non-Small Cell Lung Cancer with Limited Spread

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Pain+1

Recruiting

Comparing Buprenorphine/Naloxone and Methadone for Opioid Use Disorder in Patients with Chronic Pain: A Study on Reducing Opioid Misuse

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Buprenorphine

Bladder cancer

Recruiting

Study comparing BCG and combination of BCG with electromotive mitomycin-C treatment in patients with high-risk non-muscle-invasive bladder cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin

Glioma

Recruiting

Study of Temozolomide and Lomustine Followed by Radiotherapy versus Standard Treatment in Patients with Newly Diagnosed Grade 2 or 3 Glioma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lomustine

Colitis ulcerative+1

Recruiting

Study of adalimumab and infliximab dose adjustment guided by fecal calprotectin monitoring in adolescents and young adults with Crohn's disease or ulcerative colitis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Adalimumab

Acute lymphocytic leukaemia recurrent+1

Recruiting

Study on CD19+ Lymphoid Disease Using Genetically Modified T Cells for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:T Lymphocytes Transduced With A Rv-Sfg.cd19.Cd28.4-1Bbzeta Retroviral Vector

Cystic fibrosis

Recruiting

Study of VX-121, Tezacaftor, and Deutivacaftor for Children Aged 1-11 with Cystic Fibrosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Deutivacaftor

Acute myocardial infarction

Recruiting

Study on the Safety of Ticagrelor and Aspirin in Patients with ST-Elevation Myocardial Infarction After Heart Procedure

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.